Recent Updates
Recently added Catalysts
MGNX Negative Sentiment Score: 15/100

MACROGENICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been initiated against MacroGenics, Inc. due to allegations of misleading investors about the safety data from its TAMARACK Phase 2 trial of vobramitamab duocarmazine. This follows the revelation of five fatalities associated with the treatment, which led to a drastic 77.4% drop in share price. Affected investors are encouraged to contact the law firm Bragar Eagel & Squire for more information. The lawsuit covers securities purchased or acquired between March 7 and May 9, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against MacroGenics for alleged misrepresentations.
  • Significant decline in share price by approximately 77.4% following negative news.
  • Five fatal outcomes reported in the TAMARACK Phase 2 study raise serious safety concerns.

Full Press Release Details

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired MacroGenics securities between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”). Investors have until September 24, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
On May 9, 2024, MacroGenics announced in a press release that a total of five fatal outcomes had occurred in its TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic astration resistant prostate cancer. On this news, the price of MacroGenics shares declined by $11.36 per share, or approximately 77.4%, from $14.67 per share on May 9, 2024 to close at $3.31 on May 10, 2024.
The lawsuit alleges that the Company made material misrepresentations by providing overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to early interim safety data results from the TAMARACK Phase 2 study.
If you purchased or otherwise acquired MacroGenics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What lawsuit has been filed against MacroGenics?

A class action lawsuit was filed for MacroGenics securities purchased between March 7, 2024, and May 9, 2024.

When is the deadline to apply as lead plaintiff?

Investors must apply to the Court by September 24, 2024, to become lead plaintiff.

What caused the decline in MacroGenics stock price?

The stock price dropped after five fatal outcomes were reported in a clinical study.

Who should contact Bragar Eagel & Squire regarding the case?

Anyone who purchased MacroGenics shares and suffered a loss or has relevant information.

What is Bragar Eagel & Squire, P.C. known for?

The firm specializes in representing investors in securities and complex litigation cases.

Last updated: Jul 31, 2024